{"id":1424,"date":"2010-10-11T09:39:03","date_gmt":"2010-10-11T13:39:03","guid":{"rendered":"http:\/\/sciencebusiness.technewslit.com\/?p=1424"},"modified":"2010-10-11T09:39:03","modified_gmt":"2010-10-11T13:39:03","slug":"immunogen-novartis-to-collaborate-on-cancer-drugs","status":"publish","type":"post","link":"https:\/\/technewslit.com\/sciencebusiness\/?p=1424","title":{"rendered":"ImmunoGen, Novartis to Collaborate on Cancer Drugs"},"content":{"rendered":"<p><a href=\"http:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/10\/DrugVials_HeyPaul.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"alignright size-full wp-image-1427\" title=\"DrugVials_HeyPaul\" src=\"http:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/10\/DrugVials_HeyPaul.jpg\" alt=\"Drug vials (Hey Paul\/Flickr)\" width=\"212\" height=\"200\" srcset=\"https:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/10\/DrugVials_HeyPaul.jpg 212w, https:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/10\/DrugVials_HeyPaul-150x141.jpg 150w\" sizes=\"auto, (max-width: 212px) 100vw, 212px\" \/><\/a><a href=\"http:\/\/www.immunogen.com\/wt\/home\/home\">ImmunoGen Inc.<\/a>, a biotechnology company in Waltham, Massachusetts, said today it has a collaboration agreement with Novartis to discover and develop targeted anticancer therapeutics using antibodies to several antigen targets to be named by <a href=\"http:\/\/www.novartis.com\/\">Novartis<\/a>, a pharmaceutical manufacturer headquartered in Basel, Switzerland.<\/p>\n<p>Under the agreement, Novartis will pay a $45 million fee to ImmunoGen for exclusive rights to use the company&#8217;s Targeted Antibody Payload (TAP) technology with antibodies to the antigen targets specified by Novartis. ImmunoGen says a TAP compound consists of a tumor-targeting manufactured antibody with a cancer-killing agent attached as a payload. The antibody delivers the payload specifically to tumor cells. Seven TAP compounds are now in clinical testing, either through ImmunoGen&#8217;s own product programs and those of its partners.<\/p>\n<p>The agreement also provides that for each target resulting in an anticancer therapeutic, ImmunoGen is entitled to receive milestone payments potentially totaling $200.5 million plus royalties on any product sales. ImmuGen also will also be compensated for research and any manufacturing done on behalf of Novartis.<\/p>\n<p>Related: <a href=\"http:\/\/sciencebusiness.technewslit.com\/?p=1364\">Novartis to Develop Flu Vaccines with Synthetic Genomics<\/a><\/p>\n<p>Photo: <a href=\"http:\/\/www.flickr.com\/photos\/heypaul\/2101849662\/sizes\/l\/in\/photostream\/\">Hey Paul\/Flickr<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>ImmunoGen Inc., a biotechnology company in Waltham, Massachusetts, said today it has a collaboration agreement with Novartis to discover and develop targeted anticancer therapeutics using antibodies to several antigen targets to be named by Novartis, a pharmaceutical manufacturer headquartered in Basel, Switzerland. Under the agreement, Novartis will pay a $45 million fee to ImmunoGen for [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16],"tags":[21,51,27],"class_list":["post-1424","post","type-post","status-publish","format-standard","hentry","category-ventures","tag-biotech","tag-cancer","tag-pharmaceuticals"],"_links":{"self":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/1424","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1424"}],"version-history":[{"count":4,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/1424\/revisions"}],"predecessor-version":[{"id":1429,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/1424\/revisions\/1429"}],"wp:attachment":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1424"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1424"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1424"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}